Preliminary Report - ID Mapping
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | Next revision Both sides next revision | ||
|
covid:unpublished [2020/08/05 13:14] biogridadmin |
covid:unpublished [2020/08/05 13:15] biogridadmin |
||
|---|---|---|---|
| Line 5: | Line 5: | ||
| **WARNING** - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. | **WARNING** - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. | ||
| - | |||
| - | ^ Custom ID ^ DOI ^ Author ^ Dataset ^ | ||
| - | | **888800000001** | **[[https://doi.org/10.1101/2020.03.22.002386|10.1101/2020.03.22.002386]]** | Gordon DE (2020) | **[[https://thebiogrid.org/220839/publication|A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]]** | | ||
| - | | **888800000002** | **[[https://doi.org/10.1101/2020.03.29.20041962|10.1101/2020.03.29.20041962]]** | Gao T (2020) | **[[https://thebiogrid.org/221112/publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** | | ||
| - | | **888800000003** | **[[https://doi.org/10.1101/2020.02.16.951723|10.1101/2020.02.16.951723]]** | Sun C (2020) | **[[https://thebiogrid.org/221178/publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** | | ||
| - | | **888800000004** | **[[https://doi.org/10.1101/2020.03.16.994236|10.1101/2020.03.16.994236]]** | Procko E (2020) | **[[https://thebiogrid.org/221182/publication|The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2]]** | | ||
| - | | **888800000005** | **[[https://doi.org/10.1101/2020.03.14.988345|10.1101/2020.03.14.988345]]** | Wang K (2020) | **[[https://thebiogrid.org/221183/publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** | | ||
| - | | **888800000006** | **[[https://doi.org/10.1101/2020.02.17.951848|10.1101/2020.02.17.951848]]** | Zhou Q (2020) | **[[https://thebiogrid.org/221185/publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]** | | ||
| - | | **888800000008** | **[[https://doi.org/10.1101/2020.03.29.013490|10.1101/2020.03.29.013490]]** | Wang C (2020) | **[[https://thebiogrid.org/221195/publication|Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2]]** | | ||
| - | | **888800000009** | **[[https://doi.org/10.1101/2020.03.25.996348|10.1101/2020.03.25.996348]]** | Dai W (2020) | **[[https://thebiogrid.org/221196/publication|Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease]]** | | ||
| - | | **888800000010** | **[[https://doi.org/10.1101/2020.03.15.992883|10.1101/2020.03.15.992883]]** | Joyce MG (2020) | **[[https://thebiogrid.org/221197/publication|A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein]]** | | ||
| - | | **888800000011** | **[[https://doi.org/10.1101/2020.03.16.993386|10.1101/2020.03.16.993386]]** | Gao Y (2020) | **[[https://thebiogrid.org/221198/publication|Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target]]** | | ||
| - | | **888800000012** | **[[https://doi.org/10.1101/2020.03.31.019216|10.1101/2020.03.31.019216]]** | Liang Q (2020) | **[[https://thebiogrid.org/221199/publication|Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis]]** | | ||
| - | | **888800000013** | **[[https://doi.org/10.1101/2020.04.15.042085|10.1101/2020.04.15.042085]]** | Bestle D (2020) | **[[https://thebiogrid.org/221402/publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]** | | ||
| - | | **888800000016** | **[[https://doi.org/10.1101/2020.04.14.042010|10.1101/2020.04.14.042010]]** | Chi X (2020) | **[[https://thebiogrid.org/221405/publication|Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain]]** | | ||
| - | | **888800000017** | **[[https://doi.org/10.1101/2020.04.06.20055475|10.1101/2020.04.06.20055475]]** | Ye L (2020) | **[[https://thebiogrid.org/221565/publication|Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor]]** | | ||
| - | | **888800000018** | **[[https://doi.org/10.1101/2020.04.19.049643|10.1101/2020.04.19.049643]]** | Zeng X (2020) | **[[https://thebiogrid.org/221566/publication|Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy]]** | | ||
| - | | **888800000019** | **[[https://doi.org/10.1101/2020.04.23.057265|10.1101/2020.04.23.057265]]** | Peng Q (2020) | **[[https://thebiogrid.org/221567/publication|Structural and biochemical characterization of nsp12-nsp7-nsp8 core polymerase complex from COVID-19 virus]]** | | ||
| - | | **888800000020** | **[[https://doi.org/10.1101/2020.04.22.046565|10.1101/2020.04.22.046565]]** | Liu Y (2020) | **[[https://thebiogrid.org/221568/publication|Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2]]** | | ||
| - | | **888800000021** | **[[https://doi.org/10.1101/2020.04.21.053017|10.1101/2020.04.21.053017]]** | Walker A (2020) | **[[https://thebiogrid.org/221569/publication|Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases]]** | | ||
| - | | **888800000022** | **[[https://doi.org/10.1101/2020.04.17.047498|10.1101/2020.04.17.047498]]** | Rosas Lemus M (2020) | **[[https://thebiogrid.org/221570/publication|The crystal structure of nsp10-nsp16 heterodimer from SARS CoV-2in complex with S-adenosylmethionine]]** | | ||
| - | | **888800000023** | **[[https://doi.org/10.1101/2020.04.19.048710|10.1101/2020.04.19.048710]]** | Zhao X (2020) | **[[https://thebiogrid.org/221571/publication|Broad and differential animal ACE2 receptor usage by SARS-CoV-2]]** | | ||
| - | | **888800000024** | **[[https://doi.org/10.1101/2020.04.26.061705|10.1101/2020.04.26.061705]]** | Viswanathan T (2020) | **[[https://thebiogrid.org/221642/publication|Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus]]** | | ||
| - | | **888800000025** | **[[https://doi.org/10.1101/2020.04.29.068890|10.1101/2020.04.29.068890]]** | Rut W (2020) | **[[https://thebiogrid.org/221777/publication|Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design]]** | | ||
| - | | **888800000026** | **[[https://doi.org/10.1101/2020.04.27.063180|10.1101/2020.04.27.063180]]** | Hillen HS (2020) | **[[https://thebiogrid.org/221778/publication|Structure of replicating SARS-CoV-2 polymerase]]** | | ||
| - | | **888800000027** | **[[https://doi.org/10.1101/2020.04.29.068098|10.1101/2020.04.29.068098]]** | Sun Z (2020) | **[[https://thebiogrid.org/221779/publication|Mass spectrometry analysis of newly emerging coronavirus HCoV-19 spike S protein and human ACE2 reveals camouflaging glycans and unique post-translational modifications]]** | | ||
| - | | **888800000028** | **[[https://doi.org/10.1101/2020.05.03.073080|10.1101/2020.05.03.073080]]** | Vuong W (2020) | **[[https://thebiogrid.org/221830/publication|Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication]]** | | ||
| - | | **888800000029** | **[[https://doi.org/10.1101/2020.05.02.20086876|10.1101/2020.05.02.20086876]]** | Zhang D (2020) | **[[https://thebiogrid.org/221831/publication|Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in environmental specimens via surface enhanced Raman scattering (SERS)]]** | | ||
| - | | **888800000030** | **[[https://doi.org/10.1101/2020.05.05.079202|10.1101/2020.05.05.079202]]** | Huo J (2020) | **[[https://thebiogrid.org/221832/publication|Neutralization of SARS-CoV-2 by destruction of the prefusion Spike]]** | | ||
| - | | **888800000031** | **[[https://doi.org/10.1101/2020.05.06.079830|10.1101/2020.05.06.079830]]** | Zha L (2020) | **[[https://thebiogrid.org/221833/publication|Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles]]** | | ||
| - | | **888800000032** | **[[https://doi.org/10.1101/2020.05.02.043554|10.1101/2020.05.02.043554]]** | Gunther S (2020) | **[[https://thebiogrid.org/221835/publication|Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease]]** | | ||
| - | | **888800000033** | **[[https://doi.org/10.1101/2020.05.01.20077743|10.1101/2020.05.01.20077743]]** | Wu Y (2020) | **[[https://thebiogrid.org/221836/publication|A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2]]** | | ||
| - | | **888800000034** | **[[https://doi.org/10.1101/2020.05.03.074914|10.1101/2020.05.03.074914]]** | Liu X (2020) | **[[https://thebiogrid.org/221959/publication|Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection]]** | | ||
| ^ Custom ID ^ DOI ^ AUTHOR ^ DATASET ^ | ^ Custom ID ^ DOI ^ AUTHOR ^ DATASET ^ | ||